
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Synteract, a CRO providing full-service Phase I-IV clinical trials, has acquired Cu-Tech, a dermatology specialist CRO. With this acquirement, Synteract has created a dedicated center of dermatology development.
Read the full release






